Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.

Massimo Terzolo | Martin Fassnacht | Paola Perotti | Rossella Libé | Darko Kastelan | André Lacroix | Wiebke Arlt | Harm Reinout Haak | Paola Loli | Bénédicte Decoudier | Helene Lasolle | Marcus Quinkler | Magalie Haissaguerre | Olivier Chabre | Philippe Caron | Antonio Stigliano | Roberta Giordano | Maria Chiara Zatelli | Irina Bancos | Maria Candida Barisson Villares Fragoso | Letizia Canu | Michaela Luconi | Soraya Puglisi | Vittoria Basile | Giuseppe Reimondo | Matthias Kroiss | Felix Megerle | Stefanie Hahner | Otilia Kimpel | Tina Dusek | Svenja Nölting | Isabelle Bourdeau | Vasileios Chortis | Madeleine Hester Ettaieb | Deborah Cosentini | Salvatore Grisanti | Eric Baudin | Paola Berchialla | Francesca Bovis | Maria Pia Sormani | Paolo Bruzzi | Felix Beuschlein | Jerome Bertherat | Alfredo Berruti
The lancet. Diabetes & endocrinology | 2023

Adjuvant treatment with mitotane is commonly used after resection of adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of recurrence is not high. We aimed to assess the efficacy and safety of adjuvant mitotane compared with surveillance alone following complete tumour resection in patients with adrenocortical carcinoma considered to be at low to intermediate risk of recurrence.

Pubmed ID: 37619579 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


ClinicalTrials.gov (tool)

RRID:SCR_002309

Registry and results database of federally and privately supported clinical trials conducted in United States and around world. Provides information about purpose of trial, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals.Offers information for locating federally and privately supported clinical trials for wide range of diseases and conditions. Research study in human volunteers to answer specific health questions. Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings. ClinicalTrials.gov contains trials sponsored by National Institutes of Health, other federal agencies, and private industry. Studies listed in database are conducted in all 50 States and in 178 countries.

View all literature mentions

EORTC (tool)

RRID:SCR_004070

An independent pan-European clinical research organization to improve the standards of cancer care through the multidisciplinary multinational efforts of basic scientists and clinicians. The efforts include the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use. They also contribute to the development of new drugs and other approaches in partnership with the pharmaceutical industry which is accomplished mainly by conducting large, multicenter, prospective, randomized, phase III clinical trials. The EORTC Network comprises over 300 hospitals and cancer centers in over 30 countries which include some 2,500 collaborators from all disciplines involved in cancer treatment and research. The EORTC Headquarters staff handle some 6,000 new patients enrolled each year in cancer clinical trials, approximately 30 protocols that are permanently open to patient entry, over 50,000 patients who are in follow-up, and a database of more than 180,000 patients. Intergroup collaboration is also promoted to face current challenges of clinical trials aiming at targeted therapies in order to recruit a large number of patients within a reasonable period of time.

View all literature mentions